OTTAWA, Dec. 24, 2014 /CNW/ -
The issue:
"Jetfuel Superburn" is being recalled after Health Canada tests confirmed it contains two undeclared amphetamine-like drug substances that pose serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution of Terrebonne, Quebec, is recalling the product from retail stores across Canada. Jetfuel Superburn is promoted for body building purposes, including for weight loss and increased energy.
What consumers should do
Who is affected:
Canadians who have bought or used products labelled as "Jetfuel Superburn."
Products affected:
Jetfuel Superburn (with NPN 80041638 on the label)
Jetfuel Superburn (labelled as a "Maximum Strength" Dietary Supplement with no NPN)
What Health Canada is doing:
Health Canada is monitoring the recall, and is working to identify additional retailers and distributors in order to remove these products from sale. Should additional products or issues be identified, Health Canada will take appropriate action and inform Canadians.
Background:
Health Canada tested two products labelled as "Jetfuel Superburn"– one an authorized product with a Natural Product Number (NPN) on the label, the other labelled as an "Extra Strength" Dietary Supplement without an NPN. The tests detected amphetamine-like stimulants beta-methylphenethylamine and phenylpropylmethylamine in both products.
Amphetamine stimulants can increase blood pressure, heart rate and body temperature; lead to serious cardiovascular complications (including stroke) at high doses; suppress sleep and appetite, and be addictive. Jetfuel Superburn also contains caffeine, which can increase these effects when combined with beta-methylphenethylamine and phenylpropylmethylamine.
How to report side effects to health products to Health Canada:
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.
Également disponible en français
PDF available at: http://stream1.newswire.ca/media/2014/12/24/20141224_C8638_PDF_EN_9837.pdf
PDF available at: http://stream1.newswire.ca/media/2014/12/24/20141224_C8638_PDF_EN_9838.pdf
SOURCE: Health Canada
Media Enquiries: Health Canada, (613) 957-2983; Public Enquiries: (613) 957-2991, 1-866 225-0709
Share this article